Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 7/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7925690 | 1.00 | IL6ST (0.51) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL19018652 | 1.00 | IL6ST (0.51) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5515125 | 1.00 | IL6ST (0.51) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL1194246 | 1.00 | IL6ST (0.51) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5858039 | 0.91 | IL6ST (0.45) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5501689 | 0.91 | IL6ST (0.45) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5501688 | 0.91 | IL6ST (0.45) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5496798 | 0.91 | IL6ST (0.45) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5500578 | 0.91 | IL6ST (0.48) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL7172107 | 0.91 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | IL6ST 2859/4885PPARA 1551/4885NAAA 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.